AHMEDABAD, India: In a significant move to reinforce its global footprint in the biosimilars market, Intas Pharmaceuticals, along with its global subsidiaries under the Accord brand, has completed the acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc.—establishing the company as one of the world’s largest suppliers of pegfilgrastim.
UDENYCA®, a biosimilar to Neulasta®, expands the FDA-approved biosimilar portfolio of Intas and Accord and strengthens their presence in key international markets. Accord, already a market leader in Europe and the first to introduce a biosimilar pegfilgrastim with an autoinjector, continues to outpace competitors through innovation and accessibility.
In the U.S., Accord BioPharma, Intas’ specialty division, will continue UDENYCA’s commercialization. The drug is indicated to reduce infection risk caused by febrile neutropenia in cancer patients receiving myelosuppressive chemotherapy. UDENYCA offers three convenient formulations: autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)—making treatment easier in both clinical and home-care settings. Over 300,000 patients have already benefited from the drug, with more than 1.4 million units distributed since its launch.
“This acquisition is a pivotal milestone,” said Chrys Kokino, U.S. President of Accord BioPharma. “It enhances our capabilities, strengthens our biosimilar portfolio, and reaffirms our mission to deliver affordable and effective therapies to more patients across the globe.”
The acquisition also includes the integration of key Coherus BioSciences personnel across departments such as sales, marketing, finance, supply chain, and quality. Their expertise will support seamless operations, expand services, and uphold product quality and availability during the transition.
Paul Tredwell, Executive Vice-President of Accord EMENA, emphasized the strategic importance of the deal. “With three unique delivery options for UDENYCA®, we’re reinforcing our leadership and deepening our global reach in the pegfilgrastim space.”
Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, added, “UDENYCA exemplifies our unwavering commitment to improving access to cutting-edge biologics. This acquisition cements our role as a global biosimilar leader and aligns with our vision to expand specialty care across high-impact markets.”
UDENYCA is indicated to:
Important Safety Information includes serious warnings such as splenic rupture, acute respiratory distress syndrome (ARDS), allergic reactions, and sickle cell crises. Full prescribing details and adverse reaction reports are available via UDENYCA’s official communication channels.
The deal was facilitated by legal advisors at Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
About Intas Pharmaceuticals
A pioneer in India’s biosimilar space, Intas has introduced key treatments such as Pegasta, Mabtas, and Razumab. Its products are manufactured at EU-GMP certified facilities near Ahmedabad.
www.intaspharma.com
Accord BioPharma focuses on oncology, immunology, and critical care. With a deep biosimilar pipeline, the company is committed to expanding affordable and high-quality treatment options in the U.S.
www.accordbiopharma.com
A commercial-stage biopharma company dedicated to immunotherapies for cancer, with proven expertise in oncology and biosimilar markets.
www.coherus.com
As enterprises scale rapidly across cloud platforms, the challenge is no longer just about infrastructure,…
From a mango farm battling monsoon humidity in Odisha to high-altitude observation posts perched at…
India’s mobility landscape is undergoing a profound transformation, driven by digital adoption, changing consumer expectations,…
Landmark investment establishes world-class AI infrastructure and Centres of Excellence with global technology and research…
Visit underscores the growing strategic role of indigenous drone manufacturing and high-technology MSMEs in advancing…
ET Money, India’s leading full-stack wealth platform and part of the 360 ONE WAM group,…